Travatan Z is an ophthalmic solution owned by Novartis. It contains Travaprost as an active ingredient. It was first authorized for market use on 21 September, 2006. Currently, Travatan Z holds a total of 3 drug patents.
The generics of Travatan Z could potentially enter the market after 13 October, 2029. This is after the expiration of the drug's last patent on 13 October, 2029. This patent is related to the self-preservation of the aqueous pharmaceutical composition, indicating its prolonged effectiveness.
Travatan Z is typically used to decrease high pressure in the eye, a condition due to glaucoma or other eye diseases. The travoprost it contains is a prostaglandin analog that works by increasing the outflow of aqueous fluid from the eyes, thus reducing the pressure.
Travatan Z holds three major patents, all related to its self-preserved aqueous pharmaceutical compositions. The final patent protecting the Travatan Z generic version from entering the market is set to expire on 13 October, 2029. Below are the details of the patent: